The relevant information included in this section is exactly as published on the website of the National Securities Market Commission (CNMV)

Filter results
Date Title PDF
7/11/2019 First nine months 2019 results press release
5/09/2019 ROVI announces the construction of a second heparin plant in Granada
30/07/2019 First half 2019 results press release
5/07/2019 ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia
27/05/2019 The López-Belmonte family increase their interest in ROVI to 63.1%
8/05/2019 First quarter 2019 results press release
19/03/2019 Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia
26/02/2019 Full year 2018 results press release
15/02/2019 ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets
9/01/2019 ROVI acquires Falithrom® for the German market